An interventional study of Soft robotic exosuit and Neuroprosthesis in Stroke, sponsored by Boston University Charles River Campus. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Boston University Charles River Campus · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,995 studies in Stroke with a site in United States — 392 open to participants now, 490 under way, 17 of them phase 3. Stroke · United States.
Among the 1,995 studies in Stroke with a site in United States, this one is the 1,077th largest by enrollment of the 1,621 interventional ones that give a count, is one of 102 that started in 2022, is one of 1,124 with no phase, and was the 1,827th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →392 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 40–85
Carle Foundation Hospital · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–79
Neuralink Corp · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,995 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 173 · Phase 2 236 · Phase 3 126 · Phase 4 43
First in 1980; this study’s year is marked. 102 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 40 across the 1,621 interventional studies, 153 across the 363 observational. Of the 1,332 that completed or were terminated, 564 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 1,995 have an industry lead sponsor. The 10 most frequent:
Boston University Charles River Campus is the lead sponsor of 160 studies on the registry; 34 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Boston University Charles River Campus has 7 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
167 of the studies in Stroke with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
Add all 167 to your calendar (.ics) → With an account.
Among the 1,995 studies in Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to understand whether certain post-stroke patient subsets, identified from clinical, biomechanical, and neuromuscular characteristics, preferentially respond to different walking rehabilitation interventions that augment paretic limb propulsion (e.g., soft robotic exosuits or electrical stimulation neuroprostheses). The results of this work could improve post-stroke gait recovery outcomes by informing clinical decision-making to better match patients with rehabilitation devices tailored to their specific gait characteristics.
Stroke is a leading cause of long-term disability that results in slow, asymmetrical, and inefficient walking. Personalized treatments matching patients to the treatments with which they are most likely to respond are not typical but are necessary to maximize recovery.
Post-stroke hemiparesis is commonly associated with reduced paretic limb propulsion that leads to slower, less efficient walking patterns. Our team has developed and tested two rehabilitation technologies targeting paretic propulsion: i) a soft robotic exosuit that uses cables to mechanically assist ankle dorsiflexion and plantarflexion during walking; ii) a neuroprosthesis that uses functional electrical stimulation (FES) to activate the dorsiflexor and plantarflexor muscles during walking. Both technologies aim to safely improve walking speed and paretic propulsion. The objective of this study is to evaluate if certain post-stroke patient subsets, identified from baseline clinical, biomechanical, and neuromuscular characteristics, preferentially respond to propulsion rehabilitation using soft robotic exosuits or electrical stimulation neuroprostheses.
Twenty participants with chronic (>6 months) stroke will complete one baseline gait evaluation in the laboratory and two gait training sessions: i) an exosuit day and ii) a neuroprosthesis day. Each visit will include walking with/without the respective technology.
The primary aim of this study is to identify predictors of a therapeutic response (i.e., improvement in walking speed) to determine whether certain patient subsets preferentially respond to the exosuit or the neuroprosthesis. The investigators will evaluate baseline clinical, biomechanical, and neuromuscular abilities as potential predictors of a response. The investigators hypothesize that a subset of individuals will respond preferentially to each intervention and that baseline measures of gait function will predict responders to each intervention.
A secondary aim of this study is to determine the rehabilitation mechanism underlying improved walking speed after walking with the propulsion exosuit and the neuroprosthesis. Improvements in walking speed can be achieved through recovery (e.g., increased propulsion symmetry) or compensation (e.g., increased nonparetic propulsion). We will independently evaluate the underlying biomechanical changes contributing to improvements in speed and metabolic cost. We hypothesize that both the exosuit and neuroprosthesis will promote improved speed via recovery of paretic propulsion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants completed a total of two gait training visits with a gait rehabilitation device: the first visit using a neuroprosthesis, and the second visit using a soft robotic exosuit. Gait training for each visit consists of 30 minutes of goal-directed overground walking practice at a moderately fast speed with a gait rehabilitation device that provides periods of active assistance and periods of no assistance targeting the enhancement of paretic limb gait propulsion. Shorter overground and treadmill evaluations without the gait rehabilitation device will be completed immediately before and after the gait training session to assess the short-term retention of biomechanical outcomes.
Device: Soft robotic exosuit · Device: Neuroprosthesis
Participants complete a total of two gait training visits with a gait rehabilitation device: the first visit using a soft robotic exosuit, and the second visit using a neuroprosthesis. Gait training for each visit consists of 30 minutes of goal-directed overground walking practice at a moderately fast speed with a gait rehabilitation device that provides periods of active assistance and periods of no assistance targeting the enhancement of paretic limb gait propulsion. Shorter overground and treadmill evaluations without the gait rehabilitation device will be completed immediately before and after the gait training session to assess the short-term retention of biomechanical outcomes.
Device: Soft robotic exosuit · Device: Neuroprosthesis
A soft robotic exosuit is a textile-based system worn on the waist and paretic lower limb that provides assistive torques via cables connecting the front and back of the ankle to anchor points on the shank. The exosuit provides dorsiflexion assistance during swing phase for foot clearance and plantarflexion assistance during stance phase for propulsion delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
A neuroprosthesis is a textile-based, surface electrical stimulation system worn on the waist and paretic lower limb that delivers stimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides coordinated dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
Fast Walking Speed (Overground)
Walking speed measured without assistance from a device during walking at a self-selected fast pace using the average of two walks around a 26.6-meter track.
Time frame: Periprocedural (Before); Periprocedural (After)
Paretic Propulsion (Treadmill)
Paretic propulsion measured without assistance from a device during walking on the treadmill at a speed determined by the average walking speed during the 6-Minute Walk Test completed on the Baseline Evaluation. Paretic propulsion was calculated as the peak anterior-posterior ground reaction force of the paretic limb.
Time frame: Periprocedural (Before); Periprocedural (After)
Energy Cost of Walking (Treadmill)
Energy cost measured without assistance from a device during walking on the treadmill at a speed determined by the average walking speed during the 6-Minute Walk Test completed on the Baseline Evaluation. Energy cost is measured using indirect calorimetry on a breath-by-breath basis and is calculated as the net oxygen consumption (mL/min) during walking with respect to standing rest and normalized by bodyweight (kg) and speed (m/s). Equation: energy cost (mL/kg/m) = \[Oxygen\_walking(mL/min) - Oxygen\_stand(mL/min)\] / Bodyweight(kg) / Speed(m/s) \* 60(s/min).
Time frame: Periprocedural (Before); Periprocedural (After)
| Milestone | Neuroprosthesis Training Followed by Exosuit Training | Exosuit Training Followed by Neuroprosthesis Training |
|---|---|---|
| Started | 10 | 12 |
| Received training | 10 | 12 |
| Completed | 10 | 12 |
| Not completed | 0 | 0 |
| Milestone | Neuroprosthesis Training Followed by Exosuit Training | Exosuit Training Followed by Neuroprosthesis Training |
|---|---|---|
| Started | 10 | 12 |
| Completed | 10 | 12 |
| Not completed | 0 | 0 |
| Milestone | Neuroprosthesis Training Followed by Exosuit Training | Exosuit Training Followed by Neuroprosthesis Training |
|---|---|---|
| Started | 10 | 12 |
| Received training | 10 | 12 |
| Completed | 10 | 12 |
| Not completed | 0 | 0 |
Walking speed measured without assistance from a device during walking at a self-selected fast pace using the average of two walks around a 26.6-meter track.
| meters per second (m/s) | Neuroprosthesis Training | Exosuit Training |
|---|---|---|
| Before | 1.09 ± 0.07 | 1.08 ± 0.07 |
| After | 1.17 ± 0.07 | 1.17 ± 0.07 |
Paretic propulsion measured without assistance from a device during walking on the treadmill at a speed determined by the average walking speed during the 6-Minute Walk Test completed on the Baseline Evaluation. Paretic propulsion was calculated as the peak anterior-posterior ground reaction force of the paretic limb.
| percent bodyweight (%bw) | Neuroprosthesis Training | Exosuit Training |
|---|---|---|
| Before | 10.10 ± 1.15 | 9.97 ± 1.11 |
| After | 10.27 ± 1.16 | 10.13 ± 1.08 |
Energy cost measured without assistance from a device during walking on the treadmill at a speed determined by the average walking speed during the 6-Minute Walk Test completed on the Baseline Evaluation. Energy cost is measured using indirect calorimetry on a breath-by-breath basis and is calculated as the net oxygen consumption (mL/min) during walking with respect to standing rest and normalized by bodyweight (kg) and speed (m/s). Equation: energy cost (mL/kg/m) = \[Oxygen\_walking(mL/min) - Oxygen\_stand(mL/min)\] / Bodyweight(kg) / Speed(m/s) \* 60(s/min).
| mL O2/kg/m | Neuroprosthesis Training | Exosuit Training |
|---|---|---|
| Before | 0.209 ± 0.010 | 0.209 ± 0.013 |
| After | 0.202 ± 0.008 | 0.207 ± 0.015 |
Collected over Duration of study from Baseline Evaluation to final gait training day (range: 1.14 to 6.14 weeks, average: 2.73 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Neuroprosthesis Training | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Exosuit Training | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
A total of 22 participants enrolled in the study, 10 of whom completed the neuroprosthesis training visit followed byr the exosuit training visit and 12 of whom completed the exosuit training visit followed by the neuroprosthesis training visit.
| Age, Continuous(years) | Neuroprosthesis Training First Followed by Exosuit Training | Exosuit Training First Followed by Neuroprosthesis | Total |
|---|---|---|---|
| Mean | 55.4 ± 12.5 | 59.6 ± 10.0 | 57.7 ± 11.1 |
| Sex: Female, Male(Participants) | Neuroprosthesis Training First Followed by Exosuit Training | Exosuit Training First Followed by Neuroprosthesis | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 9 | 10 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Neuroprosthesis Training First Followed by Exosuit Training | Exosuit Training First Followed by Neuroprosthesis | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 10 | 7 | 17 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Neuroprosthesis Training First Followed by Exosuit Training | Exosuit Training First Followed by Neuroprosthesis | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 9 | 9 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Paretic Side(Participants) | Neuroprosthesis Training First Followed by Exosuit Training | Exosuit Training First Followed by Neuroprosthesis | Total |
|---|---|---|---|
| Left | 7 | 8 | 15 |
| Right | 3 | 4 | 7 |
| Chronicity(years) | Neuroprosthesis Training First Followed by Exosuit Training | Exosuit Training First Followed by Neuroprosthesis | Total |
|---|---|---|---|
| Mean | 7.4 ± 4.7 | 5.2 ± 3.6 | 6.2 ± 4.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Apr 2025, 31 months.
Results were first posted in Nov 2026, 1 year 6 months after primary completion.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 31 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston University Charles River Campus →